Current Status of Immunotherapy for B-cell Lymphoma / 肿瘤防治研究
Cancer Research on Prevention and Treatment
;
(12): 159-162, 2022.
Article
in Chinese
| WPRIM
| ID: wpr-986494
ABSTRACT
Although the first-line treatment regimens represented by R-CHOP have shown good efficacy in B-cell lymphoma, there are still some patients with recurrence and progression. With the advent of the era of tumor immunotherapy, the immunotherapy of B-cell lymphoma has been rapidly developed, including immune checkpoint inhibitors, CAR-cell, tumor microenvironment regulation, etc. This article reviews the current status of immunotherapy of B-cell lymphoma.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Cancer Research on Prevention and Treatment
Year:
2022
Type:
Article
Similar
MEDLINE
...
LILACS
LIS